Enzyme immunoassay for the quantitative determination of Abatacept (Orencia®)in serum and plasma.
This kit has been especially developed for the quantitative determination of ab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Abatacept Drug Bank Accession Number is DB01281.
Abatacept is a disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease. Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is a selective costimulation modulator - like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This results in the inhibition of autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact email@example.com
|Required Volume (µl)||10|
|Total Time (min)||105|
|Detection Limit (ng/mL)||3|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|